Sign up USA
Proactive Investors - Run By Investors For Investors

MELA Sciences shares soar after flagship MelaFind product receives PMA approval

MELA Sciences shares soar after flagship MelaFind product receives PMA approval

MELA Sciences (NASDAQ:MELA) announced Monday its flagship MelaFind product, designed to test skin lesions in association with melanoma, has received pre-market approval (PMA) from the US FDA, sending its shares up over 60%.

As of 10:17 am EDT, MELA shares rose 61.2% to $5.13. Before the bell, the skin cancer-focused medical device manufacturing company saw its shares rise over 90%.

MelaFind is a medical device intended to obtain additional information on an atypical cutaneous pigmented skin lesion, in association with melanoma, the deadliest form of skin cancer.

The device is specifically intended to be used by trained physicians, namely dermatologists, in combination with a biopsy of the lesion.

Dr. Darrell S. Rigel, Clinical Professor of Dermatology at New York University said: "MelaFind has the potential to provide dermatologists with significantly more information about indeterminate pigmented skin lesions to help us when deciding on which lesions to biopsy to detect melanoma as early as possible."

"While there have been incremental improvements in imaging tools for melanoma detection, we still primarily rely on our judgment based on a visual examination to select the lesions to biopsy; data show that this is often not enough."

Responsible for about 75% of all skin cancer-related deaths, melanoma is estimated to kill approximately 9,000 Americans in 2011 alone. If detected early, the disease is virtually completely curable. However, patients with stage IV melanoma often succumb to the disease within six to ten months.

Earlier this month, MELA received a CE mark for MelaFind, meaning that it has reached consumer standards across all 27 nations of the European Union, allowing for its sale in the EU.

Register here to be notified of future MELA Company articles
View full MELA profile

MELA Sciences Timeline

Related Articles

November 10 2016
Patent safeguards the technology at the heart of the device that offers a non-invasive method of monitoring diabetes.
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
test tubes in a laboratory
March 22 2017
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use